Wells Fargo assumed coverage of Axsome Therapeutics (AXSM) with an Overweight rating and $163 price target The firm expects the FDA to approve AXS-05 for Alzheimer’s disease agitation. Axsome should submit an application for AXS-05 in Q3 and approval would unlock a $1B-$3B opportunity in additional annual peak sales revenue, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Positive Outlook for Axsome Therapeutics Amidst SYMBRAVO’s Market Expansion and Patent Strength
- Axsome Therapeutics Receives Paragraph IV Certification Notice
- Axsome Therapeutics management to meet with Needham
- Axsome Therapeutics: Strong Sales Performance and Promising Growth Trajectory Reinforce Buy Recommendation
- Axsome Therapeutics: Strong Growth Prospects and Strategic Investments Justify Buy Rating